Showing papers by "ACADIA Pharmaceuticals Inc. published in 2015"
TL;DR: A significant risk of mortality, and severe AEs in patients with Parkinson disease receiving atypical antipsychotics is highlighted, similar to or greater than the risks seen in people with Alzheimer disease, although with a less clear-cut risk of stroke and a longer delay to increased mortality.
50 citations
TL;DR: Changing the balance between activation of NPFF receptor subtypes may provide one approach to reversing opiate tolerance, and in vitro experiments revealed that AC-263093 had equal affinity forNPFFR1 and NPFFR2, and functionally inactivated NPFF R1, in addition to its previously shown ability to activate NPFFr2.
17 citations
Journal Article•
TL;DR: Improvements on caregiver burden among pimavanserin-treated people with PDP, provide important context around the benefit-risk profile of this selective 5-HT2A inverse-agonist that has shown significant benefit on psychosis and sleep and a well-tolerated safety profile.
Abstract: OBJECTIVE: To determine the effect of pimavanserin, a selective 5-HT2A inverse-agonist, on caregiver burden. BACKGROUND: Parkinson9s Disease Psychosis (PDP) is associated with functional and cognitive decline, morbidity/mortality, and increased caregiver burden often leading to early institutionalization. Pimavanserin is a potent 5-HT2A inverse-agonist being developed for PDP. Unlike current antipsychotics, it has no dopaminergic, histaminergic, adrenergic or muscarinic activity. Pimavanserin 40mg demonstrated improvements in psychosis, nighttime sleep and daytime wakefulness in randomized controlled trials (RCTs) in PDP. RCT completers could roll into a long-term open-label study (OLS). A consented caregiver had to attend all RCT and OLS visits and complete the Zarit 22-item caregiver burden scale (CBS). METHOD: In an integrated analysis of the 6-week RCTs, CBS scores were evaluated among caregivers of 268 PDP patients in N.America who received pimavanserin 40mg or placebo. Most caregivers were spouses or other family. Continued effect was assessed in the OLS. RESULTS: Mean baseline (pretreatment) CBS scores were 30.6 for placebo (N=133) and 28.8 for pimavanserin 40mg (N=135). Significant improvement in burden was observed for the pimavanserin group (-4.8 points) over placebo (-1.1 points) at 6 weeks (p=0.0009). These results did not strongly correlate with psychosis or sleep improvements, suggesting broader benefits of pimavanserin not captured by other study measures. More caregiver benefit was observed for patients with less dementia and less co-morbid disease. In the OLS, CBS scores remained generally stable (+1-point difference) for up to 9 months.CONCLUSIONS: Improvements on caregiver burden among pimavanserin-treated people with PDP, provide important context around the benefit-risk profile of this selective 5-HT2A inverse-agonist that has shown significant benefit on psychosis and sleep and a well-tolerated safety profile. Disclosure: Dr. Aarsland has nothing to disclose. Dr. Mills has received personal compensation for activities with Acadia Pharmaceuticals, Inc. as an employee. Dr. Williams has received personal compensation for activities with ACADIA Pharmaceuticals Inc. as an employee. Dr. Chi-Burris has nothing to disclose. Dr. Karistedt has nothing to disclose. Dr. Ballard has received personal compensation for activities with Novartis, Eisai, ACADIA Pharmaceuticals, and Lundbeck Research USA, Inc. as a consultant.
5 citations